Martin Lang1, Cathy D Vocke1, Christopher J Ricketts1, Adam R Metwalli1, Mark W Ball1, Laura S Schmidt2, William M Linehan3. 1. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD. 3. Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: WML@nih.gov.
Abstract
OBJECTIVES: To characterize the clinical presentation, genomic alterations, pathologic phenotype and clinical management of microphthalmia-associated transcription factor (MITF) familial renal cell carcinoma (RCC), caused by a member of the TFE3, TFEB, and MITF family of transcription factor genes. METHODS: The clinical presentation, family history, tumor histopathology, and surgical management were evaluated and reported herein. DNA sequencing was performed on blood DNA, tumor DNA and DNA extracted from adjacent normal kidney tissue. Copy number and gene expression analyses on tumor and normal tissues were performed by Real-Time Polymerase chain reaction. TCGA gene expression data were used for comparative analysis. Protein expression and subcellular localization were evaluated by immunohistochemistry. RESULTS: Germline genomic analysis identified the MITF p.E318K variant in a patient with bilateral, multifocal type 1 papillary RCC and a family history of RCC. All tumors displayed the MITF variant and were characterized by amplification of chromosomes 7 and 17, hallmarks of type 1 papillary RCC. We demonstrated that MITF p.E318K variant results in altered transcriptional activity and that downstream targets of MiT family members, such as GPNMB, are dysregulated in the tumors. CONCLUSION: Association of the pathogenic MITF variant with bilateral and multifocal type 1 papillary RCC in this family supports its role as a risk allele for the development of RCC and emphasizes the importance of screening for MITF variants irrelevant of the RCC histologic subtype. This study identifies potential biomarkers for the disease, such as GPNMB expression, that may facilitate the development of targeted therapies for patients affected with MITF-associated RCC.
OBJECTIVES: To characterize the clinical presentation, genomic alterations, pathologic phenotype and clinical management of microphthalmia-associated transcription factor (MITF) familial renal cell carcinoma (RCC), caused by a member of the TFE3, TFEB, and MITF family of transcription factor genes. METHODS: The clinical presentation, family history, tumor histopathology, and surgical management were evaluated and reported herein. DNA sequencing was performed on blood DNA, tumor DNA and DNA extracted from adjacent normal kidney tissue. Copy number and gene expression analyses on tumor and normal tissues were performed by Real-Time Polymerase chain reaction. TCGA gene expression data were used for comparative analysis. Protein expression and subcellular localization were evaluated by immunohistochemistry. RESULTS: Germline genomic analysis identified the MITF p.E318K variant in a patient with bilateral, multifocal type 1 papillary RCC and a family history of RCC. All tumors displayed the MITF variant and were characterized by amplification of chromosomes 7 and 17, hallmarks of type 1 papillary RCC. We demonstrated that MITF p.E318K variant results in altered transcriptional activity and that downstream targets of MiT family members, such as GPNMB, are dysregulated in the tumors. CONCLUSION: Association of the pathogenic MITF variant with bilateral and multifocal type 1 papillary RCC in this family supports its role as a risk allele for the development of RCC and emphasizes the importance of screening for MITF variants irrelevant of the RCC histologic subtype. This study identifies potential biomarkers for the disease, such as GPNMB expression, that may facilitate the development of targeted therapies for patients affected with MITF-associated RCC.
Authors: Marianne Berwick; Jamie MacArthur; Irene Orlow; Peter Kanetsky; Colin B Begg; Li Luo; Anne Reiner; Ajay Sharma; Bruce K Armstrong; Anne Kricker; Anne E Cust; Loraine D Marrett; Stephen B Gruber; Hoda Anton-Culver; Roberto Zanetti; Stefano Rosso; Richard P Gallagher; Terence Dwyer; Alison Venn; Klaus Busam; Lynn From; Kirsten White; Nancy E Thomas Journal: Pigment Cell Melanoma Res Date: 2014-01-30 Impact factor: 4.693
Authors: V Launonen; O Vierimaa; M Kiuru; J Isola; S Roth; E Pukkala; P Sistonen; R Herva; L A Aaltonen Journal: Proc Natl Acad Sci U S A Date: 2001-02-27 Impact factor: 11.205
Authors: S K Sidhar; J Clark; S Gill; R Hamoudi; A J Crew; R Gwilliam; M Ross; W M Linehan; S Birdsall; J Shipley; C S Cooper Journal: Hum Mol Genet Date: 1996-09 Impact factor: 6.150
Authors: Kevin A Nguyen; Jamil S Syed; Carin R Espenschied; Holly LaDuca; Ansh M Bhagat; Alfredo Suarez-Sarmiento; Timothy K O'Rourke; Karina L Brierley; Erin W Hofstatter; Brian Shuch Journal: Cancer Date: 2017-08-08 Impact factor: 6.860
Authors: L Schmidt; F M Duh; F Chen; T Kishida; G Glenn; P Choyke; S W Scherer; Z Zhuang; I Lubensky; M Dean; R Allikmets; A Chidambaram; U R Bergerheim; J T Feltis; C Casadevall; A Zamarron; M Bernues; S Richard; C J Lips; M M Walther; L C Tsui; L Geil; M L Orcutt; T Stackhouse; J Lipan; L Slife; H Brauch; J Decker; G Niehans; M D Hughson; H Moch; S Storkel; M I Lerman; W M Linehan; B Zbar Journal: Nat Genet Date: 1997-05 Impact factor: 38.330
Authors: P Ghiorzo; L Pastorino; P Queirolo; W Bruno; M G Tibiletti; S Nasti; V Andreotti; B Bressac-de Paillerets; G Bianchi Scarrà Journal: Pigment Cell Melanoma Res Date: 2012-12-10 Impact factor: 4.693
Authors: Mariana M Cajaiba; Lisa M Dyer; James I Geller; Lawrence J Jennings; David George; Dawn Kirschmann; Stephen M Rohan; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Jeffrey S Dome; Conrad V Fernandez; Elizabeth J Perlman Journal: Cancer Date: 2018-06-15 Impact factor: 6.860
Authors: Seung-Beom Hong; HyoungBin Oh; Vladimir A Valera; Masaya Baba; Laura S Schmidt; W Marston Linehan Journal: PLoS One Date: 2010-12-29 Impact factor: 3.240
Authors: Sounak Gupta; Lori A Erickson; Christine M Lohse; Wei Shen; Beth A Pitel; Shannon M Knight; Kevin C Halling; Loren Herrera-Hernandez; Stephen A Boorjian; R Houston Thompson; Bradley C Leibovich; Rafael E Jimenez; John C Cheville Journal: JAMA Netw Open Date: 2021-11-01
Authors: Daniel M Geynisman; Jodi K Maranchie; Mark W Ball; Gennady Bratslavsky; Eric A Singer Journal: Urol Oncol Date: 2021-06-04 Impact factor: 2.954